Standout Papers

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease 2021 2026 2022 2024317
  1. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease (2021)
    Aaron B. Waxman, Ricardo Restrepo‐Jaramillo et al. New England Journal of Medicine

Immediate Impact

61 standout
Sub-graph 1 of 22

Citing Papers

Treatment algorithm for pulmonary arterial hypertension
2024 Standout
Pulmonary hypertension
2024 Standout
7 intermediate papers

Works of C. Q. Deng being referenced

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
2021 Standout
Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension
2020
and 8 more

Author Peers

Author Last Decade Papers Cites
C. Q. Deng 722 741 558 44 2.0k
Doyt L. Conn 640 308 71 64 2.7k
James S. Nelson 596 884 107 53 2.5k
Matthew Kutcher 204 285 173 67 2.3k
Gian Carlo Avanzi 255 183 103 88 2.7k
John W. Loewy 380 128 171 39 2.3k
Jordi Bas 247 267 125 46 2.3k
Helen E. Seaman 291 357 231 30 1.7k
William E. Stehbens 552 710 40 78 2.1k
Jan Waldenström 237 516 56 56 2.0k
Hajime Maeda 637 489 44 78 2.4k

All Works

Loading papers...

Rankless by CCL
2026